Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Field
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
05:05pm, Thursday, 23'rd May 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) the
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
07:08am, Tuesday, 14'th May 2024
If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
09:31am, Thursday, 02'nd May 2024
NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago.
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
07:01am, Thursday, 02'nd May 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds ma
Novocure Reports First Quarter 2024 Financial Results
07:00am, Thursday, 02'nd May 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend sur
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Thursday, 25'th Apr 2024
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will b
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Can
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
01:00pm, Monday, 01'st Apr 2024
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why NovoCure Stock Soared 18.3% This Week
06:34am, Saturday, 30'th Mar 2024
Novocure announced encouraging results from a phase 3 study of its TTFields therapy in treating brain metastases. The therapy previously failed to reach a primary endpoint in a separate study for trea
Why Novocure Stock Is Jumping Today
11:50am, Thursday, 28'th Mar 2024
Novocure announced results from a phase 3 study of its TTFields therapy in treating brain metastases. Patients treated with TTFields experienced a significant improvement in the median time to intracr
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
06:06am, Thursday, 28'th Mar 2024
NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with s
Novocure's stock surges after positive results in brain-cancer trial
02:26pm, Wednesday, 27'th Mar 2024
Novocure Ltd.'s stock soared 15% Wednesday after the company announced positive results from a late-stage trial of a medtech device to treat patients with lung cancer that has spread to their brains.
